Core Viewpoint - Kangji Medical has received shareholder approval for its privatization plan, which is expected to take effect on December 5, 2025, with the company's shares delisted from the Hong Kong Stock Exchange on December 9, 2025 [1][6]. Group 1: Privatization Details - Knight Bidco Limited's proposal to privatize Kangji Medical has been approved by shareholders, with the share cancellation price set at HKD 9.25, valuing the company at approximately USD 1.4 billion [1]. - The privatization plan is based on the Cayman Islands Companies Law and will make Kangji Medical a wholly-owned subsidiary of Knight Bidco Limited [1][6]. - The plan requires approval from the Grand Court of the Cayman Islands and will be registered before it can take effect [6]. Group 2: Financial Performance - In the first half of 2025, Kangji Medical reported revenue of CNY 497 million, an increase of 8.32% year-on-year, driven by sales growth in disposable products [2]. - The net profit attributable to shareholders was CNY 265.8 million, a slight decrease of 7.03% year-on-year [2]. - Revenue growth from 2018 to 2024 showed significant increases, with annual growth rates of 42.89%, 42.36%, 1.59%, 34.95%, 13.92%, 17.76%, and 8.92% [2]. Group 3: Industry Challenges - The Chinese medical device industry is undergoing significant structural adjustments, with intensified regulatory pressures and challenges from centralized procurement policies affecting product pricing and profit margins [3]. - Kangji Medical faces increased competition and the need for greater investment in research and development to maintain its market position [3]. - The company's stock performance has been volatile, with a significant decline from its initial listing price of HKD 23.679 to a low of HKD 3.803, resulting in a cumulative drop of over 64% [3]. Group 4: Strategic Rationale for Privatization - Kangji Medical believes that maintaining its listing status offers limited benefits and that privatization will reduce costs associated with being publicly listed [4]. - The company aims to alleviate pressure related to short-term performance metrics and focus on broader strategic decisions post-privatization [4]. - The approval of the privatization plan is seen as a significant milestone, reflecting strong support from shareholders [5].